Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACR | P10323 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 9/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.36 |
| ▸ | TUBB | P07437 | 4/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869361 | 0.87 | ACR (0.44) | ACRLMNACYP1A2HIF1ASMN1; SMN2 | |
| SCHEMBL5027206 | 0.86 | ACR (0.44) | ACRLMNACYP1A2HIF1ASMN1; SMN2 | |
| SCHEMBL8517147 | 0.86 | ACR (0.54) | ACRLMNACYP1A2HIF1ASMN1; SMN2 | |
| SCHEMBL5026552 | 0.86 | RORC (0.36) | ACRKMT2A | |
| SCHEMBL5928370 | 0.83 | ACR (0.42) | ACRLMNACYP1A2HIF1ASMN1; SMN2 | |
| SCHEMBL5031175 | 0.76 | SPPL2A (0.37) | KMT2A | |
| SCHEMBL2581362 | 0.76 | KEAP1 (0.47) | — | |
| SCHEMBL4853866 | 0.75 | RORC (0.44) | — | |
| SCHEMBL13673923 | 0.75 | RORC (0.41) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL2577609 | 0.74 | RORC (0.43) | CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-08-24 | — | — | US | disclosed |
| US-6861539-B1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040198989-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-10-07 | — | — | US | disclosed |
| US-6730669-B2 | PROPHYLACTICALLY PREVENTING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, AND TREATMENT OF A RETROVIRAL INFECTION | G. D. SEARLE & CO. | 2004-05-04 | — | — | US | disclosed |
| US-6673822-B2 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. | 2003-11-20 | — | — | US | disclosed |
| US-20030130202-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-07-10 | — | — | US | disclosed |
| EP-0813542-B1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | GETMAN DANIEL P (US) | 2002-08-15 | — | — | US | disclosed |
| US-6388132-B1 | AIDS THERAPY | G. D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| EP-1188766-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. Searle & Co. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | disclosed |
| US-6214861-B1 | ENZYME INHIBITOR; VIRICIDES | G.D. SEARLE & CO. | 2001-04-10 | — | — | US | disclosed |
| US-6150556-A | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) PROTEASE; PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS | G. D. DEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6140505-A | REACTING A BENZO FUSED HETEROCYCLIC COMPOUND WITH AN SO3 COMPLEX IN THE PRESENCE OF A WATER IMMISCIBLE, NON-REACTIVE SOLVENT, AT A TEMPERATURE OF FROM ABOUT 0 TO ABOUT 75 DEGREES C., COOLING AND THEN ADDING OXALYL HALIDE. | G. D. SEARLE & CO. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6063795-A | ENZYME INHIBITORS | G.D. SEARLE & COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| US-5972989-A | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5965601-A | NOVEL COMPOUNDS FOR INHIBITING REPLICATION OF A RETROVIRUS; TREATING HIV | G. D. SEARLE & CO. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | ACR 4161/4885LMNA 3869/4885CYP1A2 4035/4885 |
| US-20040198989-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | ACR 4065/4885LMNA 3109/4885CYP1A2 3610/4885 |
| US-20020111368-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | ACR 4161/4885LMNA 3869/4885CYP1A2 4035/4885 |
| US-20030130202-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | ACR 4065/4885LMNA 3109/4885CYP1A2 3610/4885 |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | ACR 4161/4885LMNA 3869/4885CYP1A2 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.